Targeting ewing sarcoma with anti-il1rap chimeric antigen receptor modified ex-vivo expanded natural killer cells (il1rap-car nk) and tgf-beta imprinted nk cells (car tgfbi-nk) in combination with dinutuximab and nktr-255
PEDIATRIC BLOOD & CANCER（2023）
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要